SeaStar Medical Announces Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury at International Symposium
I'm PortAI, I can summarize articles.
SeaStar Medical Holding Corporation announced positive preliminary results for its QUELIMMUNE therapy in pediatric acute kidney injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Surveillance Registry data from 21 patients showed no device-related adverse events, with survival rates of 76% at Day 28 and Day 60, and 71% at Day 90. The registry aims to confirm the therapy's safety and efficacy, supporting broader adoption and informing adult clinical trials.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments